Peter Kolchinsky Is Betting Big On Achillion Pharmaceuticals, Inc. (ACHN), Wave Life Sciences (WVE) & More Heading Into 2016
Peter Kolchinsky founded RA Capital Management in 2001 and focuses mainly on healthcare stocks.
Posts Tagged ‘NASDAQ:DYAX’
Do Hedge Funds Love Dyax Corp. (DYAX)?
As we already know from media reports and hedge fund investor letters, many hedge funds lost money in the third quarter, blaming macroeconomic conditions and unpredictable events...
Three Takeover Deals That Have Investors Excited Today
With the Fed having postponed the rate hike again, companies are taking full advantage of the low interest rates to finance their diversification and expansion plans.
Peter Kolchinsky’s New Top Healthcare Pick And Old Favorites
Peter Kolchinsky's RA Capital Management recently filed its 13F with the SEC for the reporting period of June 30.
RA Capital’s Latest Move In Alcobra Ltd (ADHD) Coming Off Hefty Second Quarter Gains
According to a recent filing with the Securities and Exchange Commission, Peter Kolchinsky's RA Capital has initiated a position in Alcobra Ltd (NASDAQ:ADHD), acquiring some 1...
Dyax Corp. (DYAX): Are Hedge Funds Right About This Stock?
Now, according to many of your fellow readers, hedge funds are viewed as delayed, old investment tools of a forgotten age.
Spectrum Pharmaceuticals, Inc. (SPPI): Are Hedge Funds Right About This Stock?
Now, according to many market players, hedge funds are viewed as bloated, outdated investment tools of a forgotten age.
QLT Inc. (USA) (QLTI): Are Hedge Funds Right About This Stock?
In the financial world, there are many indicators shareholders can use to analyze Mr. Market. A pair of the most innovative are hedge fund and insider trading activity.
Dyax Corp. (DYAX), Shire PLC (ADR) (SHPG): An Interesting Bio Play in the Blood Disorder Niche
Thousands of Americans suffer from a rare and painful disease every year. This inherited disease is called Hereditary Angioedema, or HAE for short.
Amgen, Inc. (AMGN), Bristol Myers Squibb Co. (BMY): Ovarian Cancer Drug Half Way There
The biotech giant announced today that its cancer drug trebananib combined with chemotherapy paclitaxel extended median progression-free survival in recurrent ovarian cancer patients...
Hedge Funds Are Crazy About Dyax Corp. (DYAX)
In the eyes of most traders, hedge funds are assumed to be worthless, old financial tools of yesteryear.
Is Spectrum Pharmaceuticals, Inc. (SPPI) Going to Burn These Hedge Funds?
Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) was in 12 hedge funds' portfolio at the end of the first quarter of 2013.
Do Hedge Funds and Insiders Love QLT Inc. (USA) (QLTI)?
In today’s marketplace, there are tons of metrics shareholders can use to track stocks. A couple of the most innovative are hedge fund and insider trading sentiment.
Dyax Corp. (DYAX), Mellanox Technologies, Ltd. (MLNX), Safeway Inc. (SWY) & Five of Last Week’s Biggest Losers
Let's start with Dyax Corp. (NASDAQ:DYAX). The small drugmaker shed more than a third of its value after posting disappointing quarterly results. Dyax Corp.
Here is What Hedge Funds Think About Dyax Corp. (NASDAQ:DYAX) – QLT Inc. (USA) (NASDAQ:QLTI), Cambrex Corporation (NYSE:CBM)
Is Dyax Corp. (NASDAQ:DYAX) the right investment to pursue these days? The best stock pickers are taking a bullish view.
Whoa! These 3 Stocks Thrive in Sequestration: MGIC Investment Corp. (MTG), Cree, Inc. (CREE)
Since sequestration kicked in on Saturday and The End of The World As We Know It was supposed to materialize, the Dow Jones Industrial Average has packed on an additional 164 ...
